BMS-1001

CAS No. 2113650-03-4

BMS-1001( BMS 1001 | BMS1001 )

Catalog No. M13359 CAS No. 2113650-03-4

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 181 In Stock
5MG 126 In Stock
10MG 187 In Stock
25MG 316 In Stock
50MG 437 In Stock
100MG 607 In Stock
200MG 817 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BMS-1001
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
  • Description
    A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BMS 1001 | BMS1001
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2113650-03-4
  • Formula Weight
    631.122
  • Molecular Formula
    C35H35ClN2O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Guzik K, et al. J Med Chem. 2017 Jul 13;60(13):5857-5867. 2. Chupak, L.S., and Zheng, X. Compounds useful as immunomodulators. PCT/US2014/053695, (2015).
molnova catalog
related products
  • Pembrolizumab

    Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.

  • Latikafusp

    Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.

  • Sintilimab

    Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).